单抗偶联药物.pdfVIP

7842 Vol. 10, 7842–7851, December 1, 2004 Clinical Cancer Research Featured Article Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates Che-Leung Law, Charles G. Cerveny, INTRODUCTION Kristine A. Gordon, Kerry Klussman, More than 270,000 people in the United Stated suffer from Bruce J. Mixan, Dana F. Chace, non-Hodgkin’s lymphoma. In 2001, an estimated 56,200 new cases were diagnosed, and 26,300 United States deaths were Damon L. Meyer, Svetlana O. Doronina, attributed to the disease (American Cancer Society Facts and Clay B. Siegall, Joseph A. Francisco, Figures, 2001). Non-Hodgkin’s lymphoma is frequently treated Peter D. Senter, and Alan F. Wahl with conventional chemotherapies, such as cyclophosphamide, Seattle Genetics, Inc., Bothell, Washington fludarabine, or chlorambucil, or combination therapies, such as cyclophosphamide, vincristine, and prednisolone or cyclophos- phamide, doxorubicin (Dox), vincristine, and prednisolone (1). ABSTRACT Increasingly, treatment includes rituximab (Rituxan), a chimeric The anti-CD20 antibody rituximab is useful in the monoclonal antibody (mAb) targeting